Voriconazole Injection, Powder, Lyophilized, For Solution
NDC Package 72843-441-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Voriconazole injection is voriconazole is used to treat a variety of fungal infections. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Ubi Pharma Inc., this product is identified by NDC 72843-441 and is authorized under FDA application ANDA211264.

Identification & Billing

NDC Package Code
72843-441-01
Package Description
20 mL in 1 VIAL, SINGLE-USE
Product Code
72843-441
11-Digit Billing Format
72843044101
RxNorm Crosswalk
RxCUI: 351209 - voriconazole 200 MG Injection

Clinical Specifications

Proprietary Name
Voriconazole
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
VORICONAZOLE 10 mg/mL
Pharmacologic Class
Usage Information
Voriconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Regulatory & Marketing

Labeler Name
Ubi Pharma Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA211264
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-31-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72843-441-01 identifies a specific commercial package of 20 ml in 1 vial, single-use of Voriconazole, a human prescription drug labeled by Ubi Pharma Inc.. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ubi Pharma Inc. on August 31, 2020. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Voriconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

How is this Ubi Pharma Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72843044101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72843-441-01
11-Digit CMS (5-4-2)
72843-0441-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.